Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Mayo Clinic
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
University of Washington
City of Hope Medical Center
Mayo Clinic
Mayo Clinic
Emory University
Mayo Clinic
Mayo Clinic
Mayo Clinic
University of Arizona
M.D. Anderson Cancer Center
UNICANCER
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Bispebjerg Hospital
The Netherlands Cancer Institute
Regina Elena Cancer Institute
Netherlands Working Group on Immunotherapy of Oncology
Fred Hutchinson Cancer Center
Mayo Clinic
Centre Hospitalier Universitaire de Saint Etienne
National Institutes of Health Clinical Center (CC)
The Netherlands Cancer Institute
Mayo Clinic
University of Pittsburgh
The Netherlands Cancer Institute
Fred Hutchinson Cancer Center
The Cleveland Clinic
University of Virginia
Yale University
Vanderbilt-Ingram Cancer Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Duke University
Assistance Publique Hopitaux De Marseille
National Cancer Institute (NCI)